Although immune dysfunction has been demonstrated in many patients with CML [26], it has been recently reported that immunological responses to the e14a2 BCR-ABL peptide were statistically similar to that of 5 healthy subjects with the same vaccination schedule as patients with CML [27]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.